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Abstract
Few data are available on the nephrotoxic potential of vancomycin when combined with certain b-lactam antibiotics for the treatment of
osteomyelitis (OM). A retrospective cohort study was conducted of all diabetic patients with OM treated with vancomycin plus piperacillin–
tazobactam (VPT) or vancomycin plus cefepime (VC) for at least 72 h at a VA Medical Center between 1 January 2006 and 31 December
2011. All patients with a creatinine clearance (CrCl) of ≤40 mL/min, a blood urea nitrogen/serum creatinine (SCr) ratio of ≥20 : 1 or an
absolute neutrophil count of <500 cells/mm3 were excluded. The primary outcome was development of acute renal failure (ARF), deﬁned
as an increase in SCr of 0.5 mg/dL or 50% of baseline. One hundred and thirty-nine patients met the inclusion criteria; 109 in the
piperacillin–tazobactam group and 30 in the cefepime group. Among patients receiving VPT, 29.3% (32/109) developed ARF, as compared
with 13.3% (4/30) receiving VC (p 0.099). Among patients receiving high-dose therapy (≥18 g of piperacillin–tazobactam daily or ≥3 g of
cefepime daily), 37.5% (9/24) receiving VPT and 17.6% (3/17) receiving VC developed ARF (p 0.29). A multiple logistic regression analysis
identiﬁed weight and average vancomycin trough as the only signiﬁcant predictors of ARF; the choice of VPT as therapy yielded an OR of
3.45 (95% CI 0.96–12.40; p 0.057). The authors were unable to detect a statistically signiﬁcant difference in ARF between groups; however,
the power requirement was not met. Further study with a larger patient population seems warranted.
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Background
Over 25 million people in the USA are affected by diabetes
mellitus. One of the more serious complications of diabetes is
osteomyelitis (OM) [1,2]. OM in diabetic patients is often a
polymicrobial infection involving Gram-positive organisms
(including methicillin-resistant Staphylococcus aureus (MRSA)
and methicillin-susceptible S. aureus), Enterobacteraciae, and
anaerobes [2–4]. Bone biopsy remains the reference standard
for diagnosis of OM, but, owing to its invasive nature and
complicated growth requirements, is performed less often
and/or may not yield helpful results. Because of the frequency
of polymicrobial infection and the frequent absence of
deﬁnitive culture data, patients are often continued on
broad-spectrum antibiotic treatment for 4–6 weeks [2,4].
Because of the increasing prevalence of MRSA in both the
community and hospital settings, intravenous vancomycin is a
common component of therapy for OM [2–5]. In 2009,
vancomycin dosing guidelines were released, and called for
trough levels of 15–20 mg/L when vancomycin is used to treat
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deep-seated infections, such as OM. Vancomycin had been
associated with acute renal failure (ARF) in the past, and this
was thought to be related to impurities in the early products;
however, after adoption of the higher trough goals, increasing
rates of vancomycin-associated ARF have been reported in the
literature [6–10].
This broad-spectrum empirical treatment for OM often
combines vancomycin with an agent active against Gram-
negative organisms, such as piperacillin–tazobactam or cefe-
pime [2–7]. As noted, vancomycin may precipitate ARF when
given on its own, but there are also data suggesting that rates
of ARF with vancomycin increase exponentially when it is
administered with certain antibiotics; currently, the best-stud-
ied example of this concerns vancomycin and aminoglycosides
[11]. Whereas this phenomenon of additive ARF is well
documented with vancomycin and aminoglycosides, there is a
paucity of data on the potential risk of additive ARF when
vancomycin is given with other antibiotics. We set out to
compare the potential rates of ARF between two common
empirical treatment regimens for OM: vancomycin and piper-
acillin–tazobactam (VPT), and vancomycin and cefepime (VC).
Materials and Methods
Study design
A retrospective cohort study of all diabetic patients at the VA
St Louis Health Care System treated with either VPT or VC
for OM between 1 January 2006 and 31 December 2011 was
undertaken. Diabetics who received the antibiotics of interest
and had ICD-9 code 730.20 underwent chart review to
conﬁrm the presence of OM. Inclusion criteria were a
diagnosis of diabetes, a diagnosis of OM with a determination
to treat by an infectious diseases physician, and treatment with
either VPT or VC for at least 72 h, all conﬁrmed by chart
review. Patients were excluded if their baseline creatinine
clearance (CrCl) was ≤40 mL/min, their baseline blood urea
nitrogen/serum creatinine (SCr) ratio was ≥20:1, or their
baseline absolute neutrophil count was <500 cells/mm3. Addi-
tionally, patients could not have received therapy with
intravenous acyclovir, amphotericin B, any aminoglycoside or
any vasopressor concurrently or within 48 h of antibiotic
initiation. Patients were also stratiﬁed into high-dose or
non-high-dose therapy (high-dose therapy deﬁned as ≥3 g of
cefepime per 24 h, or ≥18 g of piperacillin–tazobactam per
24 h). The primary outcome of the study was the rate of ARF,
deﬁned as an increase in baseline SCr of 50% or 0.5 mg/dL
between the two groups of patients.
To determine whether patients developed ARF, baseline
and peak SCr and blood urea nitrogen were measured, and the
baseline and nadir CrCl were calculated with the Cockroft–
Gault method. Additional data collected included site of the
index case of OM, culture data, prior diagnosis of OM (yes or
no), the b-lactam used and the dose, the total duration of
combination therapy, time to peak SCr (in days), haemoglo-
bin A1Cs within 6 months of therapy initiation and within
6 months of discontinuation, average vancomycin troughs
(calculated by adding all appropriate troughs and dividing by
the total number), receipt of loop diuretics, angiotensin-
converting enzyme (ACE) inhibitors or contrast dye while
hospitalized for the index case of OM (yes or no), total
hospital days, and whether or not amputation was required as
a part of treatment. Because all patients were followed
longitudinally by the infectious diseases team at the VA St
Louis Health Care System, both outpatient laboratory data and
inpatient data were available and used in this analysis.
Statistical analysis
In order to detect a 19% difference between groups and
achieve a power of 80%, a total of 400 patients (200 patients
treated with VPT and 200 treated with VC) were needed. The
chi-square test or Fisher’s exact test was used to compare all
non-parametric data, and Student’s t-test was used to evaluate
parametric data; an alpha level of <0.05 was considered to be
statistically signiﬁcant. Additionally, a multivariate logistic
regression analysis, considering the variables of age, weight,
total duration of therapy, use of a loop diuretic, ACE inhibitor
or contrast dye while hospitalized, average vancomycin
troughs, the choice of b-lactam, and whether or not the
patient received high-dose therapy, was performed to assess
independent risk factors for the development of ARF.
Results
A total of 139 diabetic patients with OM were included in the
study. Of these, 109 patients received VPT and 30 patients
received VC. High-dose therapy was administered to 32 VPT
patients and 17 VC patients. Baseline characteristics are shown
in Table 1, and were generally similar between groups, with
the exception of age, loop diuretic administration during
hospitalization, contrast dye administration during hospitaliza-
tion, and average CrCl nadir.
Overall, 25.9% (36/139) of all patients developed ARF.
Thirty-three per cent (12/36) of patients who developed ARF
received high-dose b-lactam therapy, as compared with 28.1%
(29/103) of patients who did not develop ARF (p 0.001). There
were no statistically signiﬁcant differences between average
total duration, average vancomycin troughs or the use of loop
diuretics, ACE inhibitors or contrast dye between patients
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who developed ARF and those who did not (speciﬁc values are
shown in Table 2).
Rates of ARF by b-lactam, those receiving high-dose therapy
and by average vancomycin trough are shown in Fig. 1. ARF
occurred in 29.3% (32/109) of VPT patients and in 13.3% (4/30)
of VC patients (p 0.09). Among patients receiving high-dose
b-lactam therapy, with average vancomycin troughs of <16 mg/
L, of between 16 and 19 mg/L, and of >19 mg/L, ARF occurred
in more patients receiving VPT than receiving VC, but the
differences were not statistically signiﬁcant.
Results from the multivariate logistic regression analysis are
shown in Table 3. The six variables reported in Table 3 (age,
weight, total duration of therapy, average vancomycin trough,
choice of piperacillin–tazobactam as the b-lactam, and the use
of high-dose therapy) were determined, by univariate analysis,
to be the most likely to affect rates of ARF. In the ﬁnal
multivariate regression analysis, only weight and average
vancomycin trough were found to have a signiﬁcant impact
on the development of ARF. The use of high-dose b-lactam
therapy did not affect the likelihood of ARF developing. The
choice of piperacillin–tazobactam as the b-lactam agent
increased the likelihood of ARF developing, but this ﬁnding
was not statistically signﬁcant.
Discussion
This study compared the rates of ARF between diabetic
patients with OM who received treatment with VPT and those
who received treatment with VC. Although all three agents are
extensively cleared through the kidneys, it appeared that
patients treated with VPT experienced a higher rate of ARF;
however, this difference was not statistically signiﬁcant (29.3%
vs. 13.3%; p 0.09). A non-signiﬁcant difference was also
observed in patients receiving high-dose therapy (31.2% vs.
17.6%; p 0.49). When average vancomycin troughs were taken
into account, there was a non-signiﬁcant, higher rate of ARF
patients receiving VPT, regardless of whether the average
trough was <16 or >19 mg/L. In a multivariate logistic
regression analysis, administration of contrast dye during
hospitalization, administration of an ACE inhibitor or receipt
of a loop diuretic did not affect a patient’s risk of developing
ARF. Although not signiﬁcant, the OR for choice of pipera-
cillin–tazobactam as a b-lactam was 3.45 (95% CI 0.96–12.4).
Although the present study was unable to demonstrate a
signiﬁcant difference in the incidence of ARF between the two
different combinations, in the overall group, and in each
subgroup, there was a consistently higher rate of ARF among
patients receiving VPT.
With the publication of vancomycin dosing guidelines
endorsing higher trough goals for many infections, retrospec-
tive reports have now been published indicating that these
higher trough goals may be leading to higher rates of
nephrotoxicity in patients receiving vancomycin. A study
conducted by Jeffres et al. [12] that retrospectively evaluated
all patients admitted to a large, tertiary-care hospital over a
6.5-year period who received vancomycin for bronchoalveolar
lavage conﬁrmed MRSA healthcare-associated pneumonia. Of
the 94 patients included in the study, 42.6% of them developed
nephrotoxicity; multiple regression analysis identiﬁed troughs
≥15 mg/L as an independent risk factor for developing
nephrotoxicity [12]. In 2010, Hermsen et al. [9] evaluated
patients receiving vancomycin for MRSA pneumonia, endocar-
ditis or OM over a 2-year period, and stratiﬁed them by mean
TABLE 1. Patient characteristics
Vancomycin +
P/T (n = 109)
Vancomycin +
cefepime
(n = 30) p
Average age (years) 62.8 58.4 0.03
Receiving high-dose
therapy, % (n)
22 (24) 56.6 (17) <0.05
Previous case(s) of
OM, % (n)
44 (48) 53.3 (16) 0.39
Average haemoglobin
A1c within
6 months of therapy
initiation (%)
7.6 7.2 0.55
Average haemoglobin
A1c within
6 months after therapy
discontinuation (%)
6.6 4.9 0.05
Loop diuretics given during
hospitalization, % (n)
22.9 (25) 46.6 (14) 0.008
ACE inhibitors given during
hospitalization, % (n)
55 (60) 50 (15) 0.34
Contrast dye given during
hospitalization, % (n)
12.8 (14) 10 (3) 0.036
Average CrCl at
initiation (mL/min)
72 80.2 0.06
Average CrCl nadir (mL/min) 55.2 69 0.003
Average time to peak SCr (days) 6.60 6.38 0.87
Average duration of
combination therapy (days)
14.7 11.3 0.19
Average vancomycin trough (mg/L) 15.8 14.5 0.48
ACE, angiotensin-converting enzyme; CrCl, creatinine clearance; OM, osteomy-
elitis; P/T, piperacillin–tazobactam; SCr serum creatinine.
TABLE 2. Characteristics of all patients with acute renal
failure
Acute renal
failure
N = 36
No acute
renal failure
N = 103 p
Average haemoglobin A1c
within 6 months of therapy
initiation (%)
7.9 7.3 0.31
Average haemoglobin A1c
within 6 months after therapy
discontinuation (%)
6.7 6.1 0.29
High-dose therapy, % (n) 33.3 (12) 28.1 (29) 0.001
Average total duration (days) 17.6 13.2 0.15
Average vancomycin trough (mg/L) 18.6 14.4 0.05
Given loop diuretics, % (n) 25 (9) 29.1 (30) 0.43
Given ACE inhibitors, % (n) 55.5 (20) 53.4 (55) 0.36
Given contrast dye, % (n) 13.8 (5) 11.6 (12) 0.05
ACE, angiotensin-converting enzyme.
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vancomycin trough (<15 mg/L or ≥15 mg/L); nephrotoxicity
occurred in 10% of patients with lower troughs and in 31% of
patients with higher troughs (p 0.04) [9]. More recently,
Horey et al. [13] conducted a retrospective chart review of
270 patients within a single Veterans Affairs Medical Center
who received vancomycin. The overall incidence of nephro-
toxicity in their evaluation was 12.6% (34/270), but a
multivariate logistic regression analysis revealed an OR of
1.14 for every 1 mg/L increase in the vancomycin trough; only
7.4% of patients in this evaluation were being treated for bone
or joint infections [13]. In an effort to pull together all of the
information gleaned from recent studies, Van Hal et al. [14]
recently completed a meta-analysis of all studies from January
1995 to April 2012 that evaluated vancomycin nephrotoxicity
and stratiﬁed troughs to <15 or ≥15 mg/L. Fifteen studies met
the author’s inclusion criteria, and they calculated an overall
OR of developing ARF of 2.67 (95% CI 1.95–3.65, p <0.01) for
patients with average vancomycin troughs of ≥15 mg/L [14].
Although it appears that vancomycin alone, particularly
when efforts are made to achieve trough levels in the 15–
20 mg/L range, is nephrotoxic, there are established data
showing that vancomycin’s nephrotoxic potential can be
increased when it is combined with certain antimicrobials.
One of the most well-studied examples is the addition of
aminoglycosides to vancomycin [6]. In a study conducted by
Rybak et al. [11], groups receiving vancomycin or aminoglyco-
sides alone, or in combination, were prospectively observed;
nephrotoxicity occurred in 5%, 11%, and 22%, respectively
(p <0.0001). These results demonstrated that vancomycin
combined with an aminoglycoside could be four times as
nephrotoxic as vancomycin alone [11].
Few studies are available that have speciﬁcally evaluated
renal dysfunction in the setting of administration of piperacil-
lin–tazobactam, with or without vancomycin. Although it was
not speciﬁcally designed to evaluate causation, a recent study
was conducted of kidney failure related to broad-spectrum
antibiotic use in an intensive-care unit setting [15]. Utilizing a
multiple-effects model, the authors found that piperacillin–
tazobactam use was associated with the lowest rate of renal
recovery of all antibiotics used (more persistent renal failure),
and that discontinuation of piperacillin–tazobactam led to an
increased renal recovery rate in these patients [15].
Data from randomized controlled trials are limited, and, of
those available, some do not speciﬁcally concern renal function
changes. In evaluations of the use of piperacillin–tazobactam
for the treatment of pneumonia or perotinitis, reported rates
of renal failure or renal function changes are generally low, and
clinically signiﬁcant differences between comparator agents
have not been detected [16–19].
When evaluated for the treatment of diabetic foot
infections with a mean treatment duration of 21–24 days,
piperacillin–tazobactam led to ARF, deﬁned as an elevated SCr
level above the upper limit of normal, in six of 30 (20%) of
patients vs. one of 32 (3.1%) of patients receiving imipenem–
cilastatin [20].
Although evidence is lacking to suggest that either compo-
nent (piperacillin or tazobactam) alone, or in combination, is
associated with an increased risk of ARF, renal protection in
certain cases has been associated with piperacillin use. Animal
model data suggest that it may attenuate the renal damage
29.3%*
(32/109)
31.2%*
(10/32)
19.5%*
(8/41)
31.2%*
(10/32)
13.3%*
(4/30)
17.6%*
(3/17)
6.6%*
(1/15)
18.1%*
(2/11)
All patients High-dose
patients
Ave. vancomycin
troughs <16
Ave vancomycin
trough 16–19
Ave. vancomycin
troughs >19
V + P/T
V + C
36.1%*
(13/36)
25%*
(1/4)
FIG. 1. Frequency of acute renal failure
by group. *No differences between V + P/
T and V + C were found to be statistically
signiﬁcant. Comparisons across groups
were not made. C, cefepime; P/T,
piperacillin–tazobactam; V, vancomycin.
TABLE 3. Logistic regression analysis
Parameter OR 95% CI p
Age 1.03 0.98–1.08 0.18
Weight (kg) 1.02 1.00–1.03 0.02
Total duration (days) 1.01 0.99–1.04 0.23
Average vancomycin trough 1.07 1.0–1.14 0.02
Choice of piperacillin–tazobactam 3.45 0.96–12.4 0.06
High-dose therapy 1.45 0.56–3.74 0.45
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associated with cisplatin and aminoglycosides; however, the
observed beneﬁts could be attributable to the sodium content
of the product [21–23].
Numerous studies have been conducted evaluating cefe-
pime’s efﬁcacy in the treatment of resistant Gram-negative
infections, but there is a paucity of data directly concerning the
drug’s role in the development of ARF. Yamamura et al. [24]
examined cefepime vs. piperacillin–gentamicin in patients with
febrile neutropenia [24]. ARF was also evaluated, and was
found to occur in 15% of patients treated with piperacillin–
gentamicin; no cases were reported in the group treated with
cefepime [24]. A meta-analysis conducted by Yahav et al. [25]
included trials evaluating both the efﬁcacy and the safety of
cefepime, and the safety analysis, across a number of trials,
found no evidence for ARF being associated with the use of
cefepime [25]. The available data, although limited, suggest that
cefepime alone, or in combination with other antibiotics, has a
low potential to increase the risk of ARF.
To the authors’ knowledge, no published study has directly
compared rates of ARF between patients treated with VPT and
those treated with VC. Regarding the rates of ARF for each
individual agent, the results reported here seem to agree with
the literature. Striving for trough goals of 15–20 mg/L in
vancomycin-treated patients has been shown to increase the
rates of ARF; however, in the population evaluated here, even
though similar average troughs were reported for both groups,
more patients treated with VPT developed ARF than those
treated with VC. There are limited data on cefepime’s
nephrotoxic potential, but the available information suggests
that it is negligible. In at least one study, piperacillin alone was
found to be somewhat renal-protective when given with
known nephrotoxins, but rates of ARF were 20% when
piperacillin–tazobactam was given for 21–24 days to patients
with diabetic foot infections. It is impossible to ascertain
causation from a retrospective study such as this, but both
these results and the available literature suggest an interaction
between aggressive dosing with vancomycin, piperacillin and
tazobactam and higher rates of ARF.
The present study is not without limitations. Although we
were unable to achieve our power, and this evaluation is
probably subject to type II error, we did observe a higher rate
of ARF in all patient subgroups treated with VPT than in those
receving VC. This study was also retrospective, and involved
patients from only one VA Medical Center. However, the
study population was quite homogeneous: all were diabetics
being treated for OM. We feel that the longer duration of
exposure to combination therapy required to treat OM was a
strength of this study; shorter durations of treatment may not
allow enough exposure time for elevations in rates of ARF to
be observed. An additional strength of the evaluation was the
inclusion of only patients with stable baseline renal function,
and controlling for the most common confounders of renal
function (use of ACE inhibitors, loop diuretics, and contrast
dye). The design of this study could be improved by including
more sites to help bolster the number of cefepime-treated
patients.
In conclusion, no statistically signiﬁcant difference in the
rates of ARF between diabetic patients being treated for OM
with VPT or VC were observed in this study. In each patient
subgroup, however, more VPT-treated patients did develop
ARF. Power was not achieved in the VC group; therefore,
given that no statistically signiﬁcant difference was found, this
evaluation carries a higher probability of type II error. We
believe that further study in this area, involving larger groups
and/or multiple sites, is warranted.
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